Foresite Labs, LLC
Known title: 10% OwnerCIK: 0002027905
Foresite Labs, LLC's purchase track record
How the stock did after each of Foresite Labs, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since July 1, 2024
Stock higher 6 months later
75%
3 months: 50%
Median 6-month return
+35.1%
3 months: +8.1%
Beat the S&P 500
50%
median +20.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/8/2026 | ALMS | $7.00M | +26.2% | +66.7% | +9.0% |
| 11/17/2025 | ALMS | $3.63M | +376.8% | +279.4% | +10.9% |
| 5/2/2025 | ALMS | $202K | -10.0% | +3.5% | +20.3% |
| 7/1/2024 | ALMS | $40.00M | -14.8% | -40.0% | +7.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALMS | ▼ Sell | Other | 1,176,470 | $0 | 4/1/2026 | View on chart |
| ALMS | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 | View on chart |
| ALMS | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 | View on chart |
| ALMS | ▼ Sell | Other | 680,486 | $0 | 4/1/2026 | View on chart |
| ALMS | ▲ Buy | Open Market | 117,647 | $2.0M | 1/8/2026 | View on chart |
| ALMS | ▲ Buy | Open Market | 294,117 | $5.0M | 1/8/2026 | View on chart |
| ALMS | ▲ Buy | Open Market | 72,212 | $533K | 11/21/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 190,500 | $1.2M | 11/19/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 117,374 | $727K | 11/18/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 50,000 | $280K | 11/17/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 150,000 | $839K | 11/17/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 20,000 | $87K | 5/6/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 25,000 | $116K | 5/2/2025 | View on chart |
| ALMS | ▼ Sell | Other | 1,122,994 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 1,944,577 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 622,344 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 1,022,398 | $0 | 7/1/2024 | View on chart |
| ALMS | ▲ Buy | Open Market | 312,500 | $5.0M | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 194,459 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 481,283 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 967,567 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 | View on chart |
| ALMS | ▼ Sell | Other | 1,703,998 | $0 | 7/1/2024 | View on chart |
| ALMS | ▲ Buy | Open Market | 2,187,500 | $35.0M | 7/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.